NCT00150215View on ClinicalTrials.gov

A First In Human Study Of PF-00184562 In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

October 31, 2005

Conditions

Schizophrenia

Interventions

DRUG

PF-00184562

DRUG

Olanzapine

Trial Locations (1)

78744

Pfizer Investigational Site, Austin

Sponsors

Lead Sponsor

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

Pfizer

INDUSTRY